Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies1. After surgery, estrogen receptor (ERα) positive breast cancer (BCa) patients are treated with adjuvant endocrine therapy2 including selective estrogen receptor modulators (SERMs) an...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Nat Genet
Main Authors: Magnani, Luca, Frige, Gianmaria, Gadaleta, Raffaella Maria, Corleone, Giacomo, Fabris, Sonia, Kempe, Mannus H., Vershure, Pernette J., Barozzi, Iros, Vircillo, Valentina, Hong, Sung-Pil, Perone, Ylenia, Saini, Massimo, Trumpp, Andreas, Viale, Giuseppe, Neri, Antonino, Ali, Simak, Colleoni, Marco Angelo, Pruneri, Giancarlo, Minucci, Saverio
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5326683/
https://ncbi.nlm.nih.gov/pubmed/28112739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ng.3773
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki